We retrospectively analyzed the performance and relevance of the SeptiFast assay in detecting Aspergillus fumigatus DNA in whole blood samples from 38 critically ill intensive care unit (ICU) patients with probable or proven invasive aspergillosis (IA) and 100 ICU patients without IA. The assay exhibited 66% sensitivity, 98% specificity, a 93% positive predictive value, and an 88% negative predictive value. A. fumigatus DNAemia was associated with poor outcome.
I
nvasive aspergillosis (IA) is a serious complication among immunosuppressed and critically ill patients. Diagnosis of IA at an early stage is challenging: Microbiology cultures exhibit low sensitivity, and invasively obtaining samples for histologic analysis from severely ill patients is often contraindicated. Serologic testing of fungal antigens such as galactomannan (GM) and ␤-D-glucan in blood or bronchoalveolar lavage (BAL) fluid is helpful, but these biological markers are not 100% specific or sensitive (1, 2) . Therefore, additional rapid and reliable noninvasive tools for diagnosing IA are needed.
PCR assays for the molecular diagnosis of IA in blood or BAL fluid have been used for more than 20 years (3) . However, the European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) did not include PCR-detected Aspergillus in its revised definitions of invasive fungal disease in 2008 because PCR assays were neither standardized nor validated at this time (4) .
A commercially available multiplex real-time PCR assay (SeptiFast [SF] ; Roche Diagnostics, Mannheim, Germany) has been developed for the rapid diagnosis of invasive bacterial and fungal infections, including Aspergillus fumigatus (5) . At our institution, SF testing of blood is often requested when systemic bacterial or fungal infection, including IA, is suspected. In this study, we retrospectively examined the utility of the SF assay in detecting A. fumigatus DNA in blood from intensive care unit (ICU) patients with or without probable or proven IA. We evaluated the prognostic importance of a diagnosis of IA on outcome.
We retrospectively analyzed EDTA-treated blood samples collected between June 2009 and June 2015 from a cohort of 3,024 adult ICU patients at the University Hospital Essen, University of Duisburg-Essen, Essen, Germany. This tertiary care center has 8 ICUs (level II/III) and specializes in hematopoietic stem cell and solid organ transplantation.
Sampling of blood for SF testing in our patient population was completely at the discretion of the treating physician and was prompted by suspicion of invasive bacterial or fungal infection. The SF assay (Roche Diagnostics, Mannheim, Germany) was performed daily during weekdays. It is a European Council (CE)-approved in vitro diagnostic reagent kit and is designed to detect the DNA of 25 clinically important bacteria and fungi, including A. fumigatus, in blood in less than 6 h (5). The minimal analytical sensitivity of A. fumigatus in spiked blood samples was determined to be 3 CFU/ml (6) .
Diagnoses of IA were based on the revised EORTC/MSG criteria (4) with a slight modification. We defined an ICU stay of longer than 4 days as an additional host factor, as previously described (6, 7) , because in one study 30% of proven IA cases in ICU patients were missed because of the absence of a host factor (7). The results of tests for the mycologic factor galactomannan (GM) were considered to be positive if the index was Ն0.5 in serum and Ն1.0 in BAL fluid. Detection of A. fumigatus in cultures was considered a mycologic factor if fungal growth was observed in at least 2 respiratory specimens (e.g., BAL fluid). Bronchial and tracheal secretions were collected by blind aspiration of the tracheal/bronchial tree using a catheter. From the 3,024 patients with an SF test, only those cases that met the following criteria were further included: Ͼ4 days on ICU, sampling of two respiratory cultures within 4 days before and after the SF test, GM results from BAL fluid or serum, and chest computed tomography (CT) scan report.
We extracted information about baseline characteristics, microbiological data, radiographic results, and antifungal therapy and outcome (after 30 days) from the charts of all patients with probable or proven IA. Of this cohort, seven patients had been included in previously reported studies (8, 9) . We also extracted this information from the charts of 100 patients without IA according to the EORTC/MSG criteria for whom the results of SF testing and the additional diagnostic workup were available. In these cases, the chest CT scan showed no abnormalities, GM from BAL fluid or serum was negative, and cultures showed no growth of A. fumigatus.
Statistical analysis was performed with GraphPad Prism (GraphPad Software, Inc., La Jolla, CA).
Results of the SF assay were positive for A. fumigatus DNA in the blood of 25 of 38 ICU patients with probable or proven IA (sensitivity, 66%) ( Table 1) . Of these 25 patients, only 2 were being treated with an antimold drug at the time of blood sampling. Most patients received voriconazole as a targeted antifungal treatment after a positive SF result. Twenty-three of the 25 patients died within 30 days (mortality, 92%) after the detection of A. fumigatus DNA by PCR. In contrast, 7 of the 13 patients' with IA and negative SF results received an antifungal treatment during blood sampling. Six of these 13 patients (46%) were alive after 30 days (mortality, 54%). In the blood samples from the 100 ICU patients without IA, the SF assay detected DNA of A. fumigatus in two cases (both were hemato-oncology patients), resulting in a specificity of 98%. The positive predictive value (PPV) of SF was calculated to be 93%; the negative predictive value (NPV) was 88%.
Combining galactomannan results together with the SF data improved diagnostic performance (71% sensitivity, 98% specificity, 93% PPV, and 90% NPV).
However, when combining culture and SF results, the sensitivity, specificity, PPV, and NPV showed the greatest improvement: 79%, 98%, 94% and 92%.
To date, it is widely debated whether Aspergillus PCR testing is valid and standardized enough to be included in the EORTC/MSG definitions, which are currently under review (2) . Here, we present the results of the first study to investigate the utility of the commercially available SF assay in detecting A. fumigatus DNA in blood from adult ICU patients classified according to the revised EORTC/MSG criteria, with a slight modification.
Two reviews or meta-analyses compared the diagnostic performance of the SF assay to that of blood culture (BC) analysis for bacteria and Candida spp. (10, 11) . These studies found that BC analysis had a sensitivity of 68% and a specificity of 86%; however, no results have been reported for assays for A. fumigatus, because this mold does not normally grow in BCs. A recent systematic literature review of Aspergillus PCR testing reported a sensitivity of 84% and a specificity of 76% in blood or serum (3). The conclusion was that there is now sufficient evidence to include this diagnostic tool in the EORTC/MSG definitions (2) . Our ability to compare the diagnostic values of the PCR assay with those found in this study is limited because our study population consists mainly of solid-organ transplant recipients, and only 3 of the 38 patients with probable or proven IA had a hematological malignancy as the underlying disease. A reason for the lower sensitivity in our study could be that in the group of PCR-negative cases with IA, 7 of 13 patients had had prior antifungal therapy at the time of blood sampling. One study involving hematological patients showed that Aspergillus PCR had better diagnostic value for antifungal drug-naive patients than for patients receiving antifungal therapy (12) . This finding was also true of our cohort. In addition, it has been shown that a combined monitoring strategy based on serum GM levels and Aspergillus DNA detection resulted in earlier diagnosis and a higher incidence of IA among high-risk hematooncology patients (13, 14) . Analyzing the results of the PCR plus GM showed a better sensitivity and PPV. Interestingly, PCR plus culture results performed the best in our patient collective: 79% sensitivity, 98% specificity, 94% NPV, and 92% PPV.
Ninety-two percent of patients died within 30 days after the detection of A. fumigatus DNA in their blood, even though nearly all of them received antifungal therapy. This observation underscores the diagnostic significance of a positive PCR result in blood. In contrast, the 30-day mortality rate was lower (54%) for patients with probable or proven IA and negative PCR results. The findings of a large multicenter study involving 563 ICU patients with 94 proven cases of IA were comparable: the mortality rate was 79% at 12 weeks (15) .
The SF assay is standardized and validated, and it includes negative and inhibition controls. Nonetheless, there is always a risk of false-positive results for A. fumigatus because of contamination during the work flow. Another drawback of this assay is that it is more expensive than a species-specific PCR analysis.
Our study is limited by its retrospective design. Thus, the results should be interpreted with caution. Furthermore, we had to modify the EORTC/MSG criteria by including a longer ICU stay as an additional host factor because the definitions were originally made for hematological patients. Another important point is that the results from our patient cohort are not comparable one-toone with results for the accuracy of Aspergillus PCR assays in highrisk hematological patients. However, here we present the first study results from a large number of critical ICU patients by using a commercially available PCR assay for A. fumigatus detection in blood. We analyzed our data only for a single positive PCR sample. An earlier study suggested that the results of two positive tests may increase the specificity of PCR assays (16) . Even so, in our study the specificity was sufficient (98%).
In conclusion, the commercially available SF assay showed promising results for diagnosing IA in adult critical ICU patients. A. fumigatus DNAemia was associated with poor outcome.
